Park Avenue Securities’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Park Avenue Securities’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,956	Closed	-$1.25M	–	1215
2022 Q4	$1.25M	Sell	10,956 -606	-5%	-$50.3K	0.02%	431
2022 Q3	$716K	Sell	11,562 -1,725	-13%	-$121K	0.01%	594
2022 Q2	$1.06M	Buy	13,287 +3,730	+39%	+$353K	0.02%	439
2022 Q1	$1M	Sell	9,557 -1,996	-17%	-$195K	0.02%	480
2021 Q4	$1.25M	Buy	11,553 +2,780	+32%	+$303K	0.02%	389
2021 Q3	$961K	Buy	8,773 +449	+5%	+$46.6K	0.02%	430
2021 Q2	$779K	Sell	8,324 -404	-5%	-$37.2K	0.02%	489
2021 Q1	$803K	Buy	8,728 +3,798	+77%	+$321K	0.02%	438
2020 Q4	$361K	Buy	4,930 +1,498	+44%	+$111K	0.01%	610
2020 Q3	$267K	Sell	3,432 -501	-13%	-$34.5K	0.01%	618
2020 Q2	$219K	Buy	+3,933	New	+$168K	0.01%	614

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Park Avenue Securities's HZNP Position: Q1 2023 in Review

Park Avenue Securities sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 10,956 shares — an estimated $1.25M sold.

Park Avenue Securities first reported a position in HZNP in Q2 2020 and held it in 11 quarters. The position peaked at $1.25M in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Park Avenue Securities reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Park Avenue Securities sold 10,956 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $1.25M.
Park Avenue Securities first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2020 and held it in 11 quarters.
Park Avenue Securities's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.25M in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Park Avenue Securities's 13F filing for Q1 2023, filed 18 Apr 2023.